Terry Fry
Concepts (461)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 39 | 2025 | 358 | 9.290 |
Why?
| | T-Lymphocytes | 58 | 2025 | 1996 | 6.200 |
Why?
| | Antigens, CD19 | 26 | 2025 | 137 | 4.390 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 80 | 3.850 |
Why?
| | Graft vs Host Disease | 20 | 2023 | 256 | 3.500 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2025 | 288 | 3.230 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2025 | 911 | 2.960 |
Why?
| | Hematopoietic Stem Cell Transplantation | 26 | 2023 | 670 | 2.880 |
Why?
| | Receptors, Antigen, T-Cell | 18 | 2023 | 716 | 2.720 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 10 | 2025 | 18 | 2.650 |
Why?
| | Immunotherapy | 16 | 2024 | 641 | 2.610 |
Why?
| | Interleukin-7 | 23 | 2012 | 62 | 2.370 |
Why?
| | Dendritic Cells | 11 | 2016 | 487 | 2.340 |
Why?
| | Cancer Vaccines | 9 | 2018 | 165 | 1.870 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2023 | 1111 | 1.770 |
Why?
| | Hematologic Neoplasms | 8 | 2023 | 159 | 1.720 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2025 | 653 | 1.700 |
Why?
| | Lymphoma, B-Cell | 8 | 2025 | 131 | 1.620 |
Why?
| | Bone Marrow Transplantation | 9 | 2023 | 292 | 1.250 |
Why?
| | Lymphocyte Transfusion | 4 | 2017 | 20 | 1.210 |
Why?
| | Adoptive Transfer | 10 | 2019 | 219 | 1.120 |
Why?
| | Graft vs Leukemia Effect | 4 | 2017 | 12 | 0.980 |
Why?
| | Mice | 45 | 2025 | 17969 | 0.960 |
Why?
| | Cytokines | 12 | 2022 | 2079 | 0.920 |
Why?
| | Animals | 61 | 2025 | 37328 | 0.910 |
Why?
| | Dipeptides | 3 | 2014 | 55 | 0.900 |
Why?
| | H-Y Antigen | 5 | 2013 | 7 | 0.880 |
Why?
| | Neoplasms | 13 | 2023 | 2731 | 0.870 |
Why?
| | T-Box Domain Proteins | 1 | 2025 | 102 | 0.870 |
Why?
| | Antigens, Neoplasm | 5 | 2019 | 320 | 0.840 |
Why?
| | Cell Line, Tumor | 16 | 2025 | 3502 | 0.830 |
Why?
| | Graft vs Tumor Effect | 3 | 2021 | 8 | 0.800 |
Why?
| | Tumor Escape | 3 | 2021 | 47 | 0.720 |
Why?
| | Humans | 111 | 2025 | 141284 | 0.720 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 10 | 0.720 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 179 | 0.690 |
Why?
| | Receptors, Cytokine | 2 | 2024 | 36 | 0.680 |
Why?
| | Immune System | 5 | 2010 | 183 | 0.680 |
Why?
| | Perforin | 1 | 2020 | 19 | 0.670 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2018 | 41 | 0.670 |
Why?
| | Thymus Gland | 6 | 2004 | 316 | 0.660 |
Why?
| | Leukemia | 5 | 2025 | 243 | 0.660 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 36 | 0.650 |
Why?
| | Retinoblastoma | 1 | 2020 | 40 | 0.650 |
Why?
| | WT1 Proteins | 2 | 2018 | 13 | 0.650 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2025 | 917 | 0.630 |
Why?
| | Myelodysplastic Syndromes | 5 | 2023 | 143 | 0.620 |
Why?
| | Recurrence | 13 | 2025 | 1108 | 0.620 |
Why?
| | Lymphoma | 2 | 2019 | 228 | 0.620 |
Why?
| | Transplantation, Homologous | 9 | 2018 | 411 | 0.610 |
Why?
| | T-Lymphocyte Subsets | 6 | 2023 | 413 | 0.600 |
Why?
| | Adjuvants, Immunologic | 4 | 2014 | 238 | 0.600 |
Why?
| | Erythropoietin | 1 | 2020 | 98 | 0.590 |
Why?
| | Allergy and Immunology | 1 | 2019 | 41 | 0.590 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 174 | 0.590 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 5866 | 0.540 |
Why?
| | Genetic Engineering | 2 | 2019 | 92 | 0.510 |
Why?
| | Boron Compounds | 2 | 2014 | 30 | 0.510 |
Why?
| | Calcitonin | 1 | 2016 | 29 | 0.510 |
Why?
| | Hematopoietic Stem Cells | 4 | 2016 | 408 | 0.500 |
Why?
| | Immunologic Memory | 8 | 2025 | 358 | 0.500 |
Why?
| | Cell Lineage | 2 | 2016 | 352 | 0.500 |
Why?
| | Child | 34 | 2023 | 22390 | 0.480 |
Why?
| | Cell Plasticity | 1 | 2016 | 37 | 0.480 |
Why?
| | Leukapheresis | 2 | 2017 | 26 | 0.470 |
Why?
| | Lymphocyte Activation | 11 | 2021 | 1136 | 0.470 |
Why?
| | Antigens, CD | 2 | 2017 | 537 | 0.460 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4414 | 0.450 |
Why?
| | Donor Selection | 1 | 2015 | 77 | 0.450 |
Why?
| | Apoptosis | 8 | 2019 | 2487 | 0.440 |
Why?
| | Homeostasis | 6 | 2006 | 632 | 0.430 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 71 | 0.430 |
Why?
| | Mice, Knockout | 7 | 2020 | 3042 | 0.420 |
Why?
| | Photopheresis | 2 | 2011 | 9 | 0.420 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 48 | 0.420 |
Why?
| | Rhabdomyosarcoma | 2 | 2014 | 62 | 0.410 |
Why?
| | Signal Transduction | 8 | 2025 | 5116 | 0.410 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 216 | 0.410 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2024 | 840 | 0.400 |
Why?
| | Recombinant Fusion Proteins | 4 | 2017 | 672 | 0.400 |
Why?
| | Boronic Acids | 1 | 2013 | 34 | 0.390 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2012 | 15 | 0.390 |
Why?
| | Lymphocyte Depletion | 8 | 2014 | 136 | 0.380 |
Why?
| | Vaccination | 2 | 2012 | 1468 | 0.380 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 211 | 0.380 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 435 | 0.370 |
Why?
| | Female | 49 | 2025 | 75814 | 0.360 |
Why?
| | Flow Cytometry | 6 | 2020 | 1182 | 0.360 |
Why?
| | Siblings | 4 | 2014 | 216 | 0.360 |
Why?
| | Antigens, CD34 | 2 | 2011 | 88 | 0.360 |
Why?
| | Mice, Inbred C3H | 4 | 2014 | 255 | 0.350 |
Why?
| | Neurotoxicity Syndromes | 2 | 2024 | 39 | 0.350 |
Why?
| | Living Donors | 3 | 2014 | 269 | 0.340 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 29 | 0.340 |
Why?
| | Protein Domains | 2 | 2025 | 305 | 0.340 |
Why?
| | Neoplasm, Residual | 3 | 2020 | 130 | 0.340 |
Why?
| | Young Adult | 18 | 2025 | 13727 | 0.340 |
Why?
| | Adult | 30 | 2025 | 39319 | 0.340 |
Why?
| | Antigen Presentation | 2 | 2009 | 213 | 0.340 |
Why?
| | Neoplasm Metastasis | 3 | 2016 | 674 | 0.330 |
Why?
| | Receptors, Interleukin-7 | 5 | 2011 | 27 | 0.320 |
Why?
| | Adolescent | 23 | 2025 | 22116 | 0.320 |
Why?
| | Transplantation Conditioning | 4 | 2018 | 184 | 0.310 |
Why?
| | Lymphocyte Count | 4 | 2017 | 167 | 0.310 |
Why?
| | Gene Expression | 5 | 2020 | 1490 | 0.300 |
Why?
| | Male | 40 | 2025 | 70140 | 0.300 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2009 | 255 | 0.300 |
Why?
| | Receptors, Interferon | 1 | 2009 | 52 | 0.290 |
Why?
| | Interleukin-10 | 1 | 2011 | 305 | 0.290 |
Why?
| | Sarcoma, Ewing | 2 | 2012 | 100 | 0.290 |
Why?
| | Models, Immunological | 4 | 2020 | 101 | 0.280 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 1035 | 0.270 |
Why?
| | Monocytes | 1 | 2011 | 544 | 0.270 |
Why?
| | Remission Induction | 4 | 2017 | 306 | 0.270 |
Why?
| | Social Adjustment | 1 | 2008 | 64 | 0.270 |
Why?
| | Child, Preschool | 15 | 2023 | 11511 | 0.270 |
Why?
| | Mutation | 2 | 2015 | 4006 | 0.270 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 254 | 0.260 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 467 | 0.260 |
Why?
| | Carcinoma | 1 | 2009 | 230 | 0.260 |
Why?
| | Receptors, Antigen | 2 | 2017 | 17 | 0.250 |
Why?
| | Gene Rearrangement | 2 | 2024 | 148 | 0.250 |
Why?
| | Allografts | 3 | 2018 | 148 | 0.250 |
Why?
| | Lymphopoiesis | 2 | 2006 | 26 | 0.250 |
Why?
| | Neuroblastoma | 2 | 2021 | 162 | 0.240 |
Why?
| | Mice, Transgenic | 7 | 2021 | 2165 | 0.230 |
Why?
| | Prognosis | 7 | 2020 | 4080 | 0.230 |
Why?
| | Interferon-gamma | 1 | 2009 | 784 | 0.230 |
Why?
| | Unsupervised Machine Learning | 1 | 2025 | 23 | 0.230 |
Why?
| | Immunocompromised Host | 2 | 2010 | 201 | 0.230 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 186 | 0.220 |
Why?
| | Philadelphia Chromosome | 1 | 2024 | 19 | 0.220 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 44 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1075 | 0.220 |
Why?
| | Disease Progression | 5 | 2021 | 2808 | 0.220 |
Why?
| | Unrelated Donors | 3 | 2023 | 38 | 0.220 |
Why?
| | Tissue Donors | 4 | 2018 | 406 | 0.220 |
Why?
| | HIV Infections | 5 | 2008 | 2981 | 0.220 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 221 | 0.210 |
Why?
| | Transplantation, Autologous | 5 | 2018 | 282 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2025 | 11216 | 0.210 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2024 | 71 | 0.210 |
Why?
| | Lentivirus | 3 | 2019 | 59 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2017 | 393 | 0.200 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 33 | 0.200 |
Why?
| | Combined Modality Therapy | 4 | 2021 | 1243 | 0.200 |
Why?
| | Interleukin-15 | 4 | 2014 | 99 | 0.200 |
Why?
| | Regeneration | 2 | 2004 | 196 | 0.200 |
Why?
| | Protein Binding | 3 | 2025 | 2233 | 0.200 |
Why?
| | Macrophages | 1 | 2011 | 1478 | 0.200 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 47 | 0.190 |
Why?
| | Genetic Vectors | 3 | 2019 | 336 | 0.180 |
Why?
| | Mice, SCID | 4 | 2019 | 367 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 191 | 0.180 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 63 | 0.180 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 92 | 0.180 |
Why?
| | Microglia | 1 | 2024 | 254 | 0.180 |
Why?
| | Gangliosides | 1 | 2021 | 22 | 0.180 |
Why?
| | Lymphopenia | 4 | 2011 | 67 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2023 | 206 | 0.170 |
Why?
| | Coculture Techniques | 2 | 2012 | 244 | 0.170 |
Why?
| | Bone Marrow | 3 | 2020 | 298 | 0.170 |
Why?
| | Capillary Leak Syndrome | 1 | 2020 | 12 | 0.170 |
Why?
| | Exotoxins | 1 | 2020 | 16 | 0.170 |
Why?
| | Recovery of Function | 1 | 2005 | 684 | 0.170 |
Why?
| | Macrophage Activation Syndrome | 1 | 2020 | 22 | 0.170 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 69 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 768 | 0.170 |
Why?
| | Anxiety | 1 | 2008 | 1078 | 0.160 |
Why?
| | Immunotoxins | 1 | 2020 | 55 | 0.160 |
Why?
| | Cyclophosphamide | 4 | 2023 | 257 | 0.160 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 13 | 0.160 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 599 | 0.160 |
Why?
| | Bacterial Toxins | 1 | 2020 | 104 | 0.160 |
Why?
| | B-Lymphocytes | 4 | 2018 | 857 | 0.160 |
Why?
| | Immunodominant Epitopes | 2 | 2012 | 27 | 0.160 |
Why?
| | Clinical Studies as Topic | 1 | 2019 | 12 | 0.150 |
Why?
| | Pediatrics | 1 | 2008 | 1102 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2019 | 12 | 0.150 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 134 | 0.150 |
Why?
| | Cell Proliferation | 6 | 2024 | 2502 | 0.150 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.150 |
Why?
| | Epitopes | 2 | 2018 | 476 | 0.150 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1059 | 0.150 |
Why?
| | Immunomodulation | 1 | 2019 | 100 | 0.150 |
Why?
| | Cell Membrane | 2 | 2020 | 704 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2021 | 280 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2020 | 249 | 0.140 |
Why?
| | History, 21st Century | 1 | 2019 | 218 | 0.140 |
Why?
| | Cryopreservation | 1 | 2019 | 105 | 0.140 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2018 | 82 | 0.140 |
Why?
| | Autoantigens | 2 | 2019 | 424 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1791 | 0.140 |
Why?
| | History, 20th Century | 1 | 2019 | 324 | 0.140 |
Why?
| | Down Syndrome | 1 | 2024 | 504 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2004 | 1144 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5222 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2019 | 241 | 0.140 |
Why?
| | Graft Survival | 3 | 2011 | 502 | 0.140 |
Why?
| | Fas Ligand Protein | 2 | 2019 | 58 | 0.130 |
Why?
| | Cell Division | 3 | 2012 | 792 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2020 | 507 | 0.130 |
Why?
| | Chromatin | 2 | 2023 | 536 | 0.130 |
Why?
| | Salvage Therapy | 2 | 2023 | 154 | 0.130 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 711 | 0.130 |
Why?
| | Cell Engineering | 1 | 2017 | 14 | 0.130 |
Why?
| | Immunophenotyping | 2 | 2020 | 325 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 368 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 197 | 0.130 |
Why?
| | Spine | 1 | 2018 | 179 | 0.130 |
Why?
| | Lymph Nodes | 3 | 2013 | 494 | 0.130 |
Why?
| | Stem Cell Research | 1 | 2016 | 1 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 4 | 2008 | 273 | 0.120 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2015 | 6 | 0.120 |
Why?
| | Retrospective Studies | 9 | 2023 | 16447 | 0.120 |
Why?
| | Stem Cell Niche | 1 | 2016 | 58 | 0.120 |
Why?
| | Clone Cells | 1 | 2016 | 267 | 0.120 |
Why?
| | Infant | 8 | 2018 | 9820 | 0.120 |
Why?
| | PAX5 Transcription Factor | 1 | 2015 | 14 | 0.120 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2162 | 0.120 |
Why?
| | STAT Transcription Factors | 1 | 2015 | 16 | 0.120 |
Why?
| | Janus Kinases | 1 | 2015 | 15 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1706 | 0.120 |
Why?
| | Gene Editing | 1 | 2016 | 87 | 0.120 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 190 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 226 | 0.110 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2015 | 27 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2016 | 147 | 0.110 |
Why?
| | Cell Line | 2 | 2017 | 2863 | 0.110 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 375 | 0.110 |
Why?
| | 4-1BB Ligand | 1 | 2014 | 7 | 0.110 |
Why?
| | Aging | 3 | 2002 | 1919 | 0.110 |
Why?
| | Prospective Studies | 5 | 2023 | 7805 | 0.110 |
Why?
| | Calgranulin B | 1 | 2014 | 10 | 0.110 |
Why?
| | Growth | 1 | 1994 | 52 | 0.110 |
Why?
| | Calgranulin A | 1 | 2014 | 11 | 0.110 |
Why?
| | Models, Biological | 3 | 2009 | 1810 | 0.110 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 86 | 0.110 |
Why?
| | Survival Analysis | 2 | 2017 | 1322 | 0.110 |
Why?
| | Erythrocytes | 1 | 2020 | 698 | 0.110 |
Why?
| | Virus Replication | 1 | 2017 | 533 | 0.110 |
Why?
| | Growth Disorders | 1 | 1994 | 87 | 0.110 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1261 | 0.100 |
Why?
| | Genome | 1 | 2016 | 303 | 0.100 |
Why?
| | Phenotype | 4 | 2019 | 3172 | 0.100 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2014 | 75 | 0.100 |
Why?
| | Attitude to Health | 2 | 2008 | 451 | 0.100 |
Why?
| | Body Height | 1 | 1994 | 200 | 0.100 |
Why?
| | Alternative Splicing | 1 | 2015 | 232 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2014 | 173 | 0.100 |
Why?
| | Recombinant Proteins | 6 | 2011 | 1362 | 0.100 |
Why?
| | Transduction, Genetic | 3 | 2019 | 135 | 0.100 |
Why?
| | fas Receptor | 2 | 2019 | 93 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 123 | 0.100 |
Why?
| | Incidence | 2 | 2018 | 2809 | 0.100 |
Why?
| | Animals, Congenic | 1 | 2012 | 9 | 0.100 |
Why?
| | Radiation Chimera | 1 | 2012 | 27 | 0.100 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2012 | 59 | 0.100 |
Why?
| | Proteins | 1 | 2019 | 1007 | 0.100 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 51 | 0.100 |
Why?
| | CD3 Complex | 3 | 2017 | 106 | 0.100 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2012 | 46 | 0.100 |
Why?
| | Treatment Failure | 2 | 2014 | 355 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2012 | 70 | 0.090 |
Why?
| | Tumor Burden | 1 | 2013 | 314 | 0.090 |
Why?
| | Antigen-Presenting Cells | 2 | 2010 | 158 | 0.090 |
Why?
| | Chemokines | 1 | 2013 | 223 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 319 | 0.090 |
Why?
| | Body Weight | 2 | 2002 | 992 | 0.090 |
Why?
| | Blood Component Removal | 1 | 2011 | 28 | 0.090 |
Why?
| | CD28 Antigens | 2 | 2025 | 57 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 775 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 661 | 0.090 |
Why?
| | CD4-CD8 Ratio | 2 | 2019 | 24 | 0.090 |
Why?
| | Methoxsalen | 1 | 2011 | 4 | 0.090 |
Why?
| | Spleen | 2 | 2011 | 512 | 0.090 |
Why?
| | Adenovirus Infections, Human | 1 | 2010 | 15 | 0.080 |
Why?
| | Brain Neoplasms | 2 | 2011 | 1282 | 0.080 |
Why?
| | Cytosine | 1 | 2010 | 48 | 0.080 |
Why?
| | Blood | 1 | 2011 | 110 | 0.080 |
Why?
| | Alleles | 1 | 2013 | 878 | 0.080 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2002 | 278 | 0.080 |
Why?
| | Organophosphonates | 1 | 2010 | 96 | 0.080 |
Why?
| | Hematopoiesis | 3 | 2016 | 193 | 0.080 |
Why?
| | Antiviral Agents | 2 | 2018 | 748 | 0.080 |
Why?
| | Acute Disease | 3 | 2023 | 1005 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 2009 | 31 | 0.080 |
Why?
| | Ophthalmoplegia | 1 | 1989 | 13 | 0.080 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 1989 | 29 | 0.080 |
Why?
| | Laryngeal Neoplasms | 1 | 1989 | 34 | 0.080 |
Why?
| | Sarcoma | 1 | 2011 | 193 | 0.070 |
Why?
| | Intestinal Neoplasms | 1 | 2009 | 31 | 0.070 |
Why?
| | Hematopoietic System | 1 | 2008 | 8 | 0.070 |
Why?
| | Virus Diseases | 1 | 2011 | 218 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2009 | 122 | 0.070 |
Why?
| | Cell Differentiation | 4 | 2023 | 1983 | 0.070 |
Why?
| | Sibling Relations | 1 | 2008 | 11 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 380 | 0.070 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2008 | 48 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 87 | 0.070 |
Why?
| | Ultraviolet Rays | 1 | 2011 | 399 | 0.070 |
Why?
| | Psychology | 1 | 2008 | 89 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 854 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2014 | 851 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2014 | 4149 | 0.070 |
Why?
| | Biomarkers | 2 | 2016 | 4180 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 959 | 0.060 |
Why?
| | Macaca fascicularis | 2 | 2007 | 69 | 0.060 |
Why?
| | Immune Tolerance | 2 | 2010 | 373 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2857 | 0.060 |
Why?
| | Ki-67 Antigen | 2 | 2004 | 111 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 243 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1050 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2004 | 26 | 0.050 |
Why?
| | Middle Aged | 8 | 2025 | 34658 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1989 | 641 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 189 | 0.050 |
Why?
| | Hemostasis | 1 | 2004 | 100 | 0.050 |
Why?
| | United States | 4 | 2018 | 15298 | 0.050 |
Why?
| | Obesity | 2 | 2022 | 3007 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 272 | 0.050 |
Why?
| | CD47 Antigen | 1 | 2023 | 43 | 0.050 |
Why?
| | Aged | 6 | 2025 | 24836 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 463 | 0.050 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2002 | 16 | 0.050 |
Why?
| | Histocompatibility Testing | 2 | 2014 | 121 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 178 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 343 | 0.040 |
Why?
| | Cohort Studies | 3 | 2014 | 5809 | 0.040 |
Why?
| | United Kingdom | 2 | 2009 | 321 | 0.040 |
Why?
| | Thymectomy | 1 | 2001 | 15 | 0.040 |
Why?
| | Body Mass Index | 1 | 2009 | 2390 | 0.040 |
Why?
| | Pyrimidines | 1 | 2024 | 510 | 0.040 |
Why?
| | Pyrazoles | 1 | 2024 | 482 | 0.040 |
Why?
| | HIV Protease Inhibitors | 1 | 2001 | 67 | 0.040 |
Why?
| | Ritonavir | 1 | 2001 | 72 | 0.040 |
Why?
| | Skin Transplantation | 1 | 2001 | 84 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1123 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 684 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 390 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 309 | 0.040 |
Why?
| | Subcutaneous Emphysema | 1 | 1999 | 1 | 0.040 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2019 | 9 | 0.040 |
Why?
| | Single-Chain Antibodies | 1 | 2019 | 17 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2011 | 2831 | 0.040 |
Why?
| | Vulva | 1 | 1999 | 24 | 0.040 |
Why?
| | Mice, Nude | 1 | 2001 | 700 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 621 | 0.040 |
Why?
| | K562 Cells | 1 | 2019 | 95 | 0.040 |
Why?
| | Up-Regulation | 3 | 2008 | 851 | 0.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1999 | 21 | 0.040 |
Why?
| | Age Factors | 3 | 2011 | 3295 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 269 | 0.040 |
Why?
| | Transgenes | 1 | 2019 | 185 | 0.040 |
Why?
| | Immunization | 1 | 2001 | 402 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2018 | 26 | 0.040 |
Why?
| | Hallucinations | 1 | 2018 | 31 | 0.040 |
Why?
| | Confusion | 1 | 2018 | 31 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 43 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 132 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 181 | 0.030 |
Why?
| | Risk Factors | 4 | 2018 | 10490 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 309 | 0.030 |
Why?
| | Steroids | 1 | 2018 | 163 | 0.030 |
Why?
| | Gene Order | 1 | 2017 | 27 | 0.030 |
Why?
| | Graft Rejection | 1 | 2001 | 545 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 190 | 0.030 |
Why?
| | Weight Loss | 1 | 2002 | 794 | 0.030 |
Why?
| | Advisory Committees | 1 | 2018 | 214 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 420 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 932 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 713 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 738 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 601 | 0.030 |
Why?
| | Protein Engineering | 1 | 2017 | 109 | 0.030 |
Why?
| | Research Subjects | 1 | 2016 | 43 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2016 | 42 | 0.030 |
Why?
| | Time Factors | 4 | 2008 | 6951 | 0.030 |
Why?
| | Medical Oncology | 1 | 2018 | 316 | 0.030 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2015 | 23 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 448 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2017 | 315 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 2002 | 853 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 385 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 5948 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 6270 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 60 | 0.030 |
Why?
| | Transplantation Chimera | 1 | 2014 | 57 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3345 | 0.030 |
Why?
| | Exons | 1 | 2015 | 352 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 859 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 448 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 251 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2929 | 0.030 |
Why?
| | Reference Values | 1 | 1994 | 803 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1007 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 815 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 411 | 0.020 |
Why?
| | Vidarabine | 1 | 2012 | 35 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2014 | 244 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 95 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 163 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 448 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 825 | 0.020 |
Why?
| | Vincristine | 1 | 2012 | 130 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 228 | 0.020 |
Why?
| | Rituximab | 1 | 2012 | 204 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1037 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 47 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 369 | 0.020 |
Why?
| | Bone Neoplasms | 1 | 2012 | 249 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 684 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2009 | 46 | 0.020 |
Why?
| | Bacteremia | 1 | 2011 | 218 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 910 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1486 | 0.020 |
Why?
| | Risk | 1 | 2011 | 903 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2008 | 75 | 0.020 |
Why?
| | Leukocytes | 1 | 2010 | 293 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 1989 | 327 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2815 | 0.020 |
Why?
| | Cell Separation | 1 | 2008 | 309 | 0.020 |
Why?
| | HLA Antigens | 1 | 2008 | 232 | 0.020 |
Why?
| | HIV | 1 | 2008 | 248 | 0.020 |
Why?
| | Cell Polarity | 1 | 2007 | 139 | 0.020 |
Why?
| | Mass Screening | 1 | 1994 | 1309 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3734 | 0.020 |
Why?
| | Body Composition | 1 | 2009 | 704 | 0.010 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 200 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2009 | 336 | 0.010 |
Why?
| | Adiposity | 1 | 2009 | 520 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 316 | 0.010 |
Why?
| | Annexin A5 | 1 | 2004 | 25 | 0.010 |
Why?
| | Interleukins | 1 | 2006 | 250 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 2765 | 0.010 |
Why?
| | Coloring Agents | 1 | 2004 | 96 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 117 | 0.010 |
Why?
| | Macaca mulatta | 1 | 2004 | 189 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2004 | 325 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1973 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 855 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2069 | 0.010 |
Why?
| | bcl-2-Associated X Protein | 1 | 2002 | 53 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 847 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 587 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2001 | 16 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 668 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2001 | 88 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1620 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 334 | 0.010 |
Why?
| | Colon | 1 | 2002 | 295 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1220 | 0.010 |
Why?
| | Pubic Bone | 1 | 1999 | 6 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1854 | 0.010 |
Why?
| | Hyperbaric Oxygenation | 1 | 1999 | 40 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3522 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 1999 | 44 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2091 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1456 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 5653 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1821 | 0.010 |
Why?
|
|
Fry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|